July 26, 2017
A retrospective real-life study of patients treated with the Ozurdex dexamethasone implant for various indications showed overall good tolerance and provided useful information on risk factors for pressure elevation.
Four hundred twenty-one eyes of 361 patients were analyzed in the SAFODEX study. They received 1,000 injections for macular edema secondary to retinal vein occlusion, diabetic macular edema, postsurgical macular edema, uveitis and other etiologies. Pre-existing ocular hypertension or glaucoma was present in 14% of eyes. Re-treatment was required in 58% of eyes, and one-third of the patients received at least three Ozurdex implants (Allergan).